| 摘要 |
The compound of formula (I), wherein: R1 is 4-pyridyl, pyrimidinyl, 4-pyridazinyl, 1,2,4-triazin-5-yl, quinolyl, isoquinolinyl, or quinazolin-4-yl ring, which ring is substituted with Y-Ra and optionally with an additional independent substituent selected from C1-4alkyl, halogen, hydroxyl, C1-4alkoxy, C1-4alkylthio, C1-4alkylsulfinyl, CH2OR12, amino, mono and di- C1-6alkyl substituted amino, an N-heterocyclyl ring which ring has from 5 to 7 members and optionally contains an additional heteroatom selected from O, S or NR15, N(R10)C(O)Rb or NHRa; R4 is phenyl, naphth-1-yl or naphth-2-yl, or a heteroaryl, which is optionally substituted by one or two substituents, each of which is independently selected, and which, for a 4-phenyl, 4-naphth-1-yl, 5-naphth-2-yl or 6-naphth-2-yl substituent, is halogen, cyano, nitro, C(Z)NR7R17, C(Z)OR16, (CR10R20)vCOR12, SR5, SOR5, OR12, halo-substituted-C1-4alkyl, C1-4 alkyl, ZC(Z)R12, NR10C(Z)R16, or (CR10R20)vNR10R20 and which, for other positions of substitution, is halogen, cyano, C(Z)NR13R14, C(Z)OR3, (CR10R20)m"COR3, S(O)mR3, OR3, halo-substituted-C1-4alkyl, C1-4alkyl, (CR10R20)m"NR10C(Z)R3, NR10S(O)m'R8, NR10S(O)m'NR7R17, ZC(Z)R3 or (CR10R20)m"NR13R14; R2 is -C(H)(A)(R22) ( where A is an optionally substituted aryl, heterocyclyl, or heteroaryl ring, or A is a substituted C1-10alkyl and R22 is an optionally substituted C1-10 alkyl) A pharmaceutical composition comprising the compound of formula (I) is also described. The compounds of formula (I) are useful for treating inflammation or for treating CSBP/RK/p38 kinase mediated diseases.
|
